Recent court proceedings involving Pretoria-based compounding pharmacy iDexis have placed semaglutide medicine safety in the spotlight. The dispute has sparked debate about access to medicines, intellectual property rights and the regulatory powers of the South African Health Products Regulatory Authority (SAHPRA). It has also drawn attention to rising demand for medicines containing semaglutide. This is the active ingredient in registered…
Tag: Compounded Medicines
-
Telehealth GLP-1 Prescribing Sparks Safety Fears
A Yale University study has identified serious weaknesses in how some telehealth providers prescribe GLP-1 weight-loss medications. The secret shopper study examined 49 online healthcare providers. Researchers used a fictional patient who met the clinical criteria for GLP-1 treatment. The findings suggest that several virtual clinics may be prioritising fast access to prescriptions over detailed medical care. This could expose…
-
iDexis Semaglutide Ban Ordered By High Court
The High Court has temporarily stopped pharmacy group iDexis from manufacturing, supplying and marketing weight-loss medicines containing semaglutide. The iDexis semaglutide ban follows an application by Danish pharmaceutical company Novo Nordisk. The company manufactures Ozempic and Wegovy. Semaglutide is the active ingredient in both medicines. Ozempic is registered as a treatment for diabetes. Wegovy is approved for weight management. The…
-
Semaglutide Compounding Dispute: Novo Nordisk Heads To Court
Danish pharmaceutical giant Novo Nordisk is taking compounding pharmacy iDexis to the Pretoria High Court. The highly anticipated legal battle will take place on June 10. The case focuses on the unauthorised scale production of semaglutide-based weight-loss injections. Novo Nordisk wants the court to stop iDexis from manufacturing, advertising, and distributing these products. The global firm alleges that iDexis is…